Kane Biotech Inc. (V:KNE)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Apr 16, 2024 09:15 am ET

Kane Biotech to Host Investor Webinar

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday April 18th, 2024 at 4:15pm Eastern Time. Marc Edwards, Kane's President & CEO, will share his thoughts on what the sale of STEM Animal...

Apr 15, 2024 09:15 am ET

Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that, it has completed the sale of its interest in STEM Animal Health Inc. to Dechra Veterinary Products, Inc. for US $8,000,000, plus net cash held in STEM (estimated at CND $600,000)...

Apr 11, 2024 10:00 am ET

Canadian Investment Regulatory Organization Trade Resumption - KNE

VANCOUVER, BC, April 11, 2024 /CNW/ - Trading resumes in:

Apr 11, 2024 09:45 am ET

Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has reached an agreement in principle for the sale of its entire interest (the “Interest”) in STEM Animal Health Inc. (“STEM”) to a third party...

Apr 11, 2024 09:04 am ET

Canadian Investment Regulatory Organization Trading Halt - KNE

VANCOUVER, BC, April 11, 2024 /CNW/ - The following issues have been halted by CIRO

Mar 26, 2024 04:05 pm ET

Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results. On December 20, 2023, Kane Biotech announced that it received a non-binding offer for its...

Mar 20, 2024 08:30 am ET

Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announces today that it has extended the exclusivity period on the offer for its interest in STEM Animal Health that it announced on December 20, 2023, from March 19,...

Mar 19, 2024 04:10 pm ET

Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce...

Mar 08, 2024 09:00 am ET

Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the Bioscience Association of Manitoba (“BAM”) annual awards dinner held on March 7, 2024, Kane Biotech received the BAM Company of the Year...

Feb 22, 2024 08:00 am ET

Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the special meeting of the shareholders of the Company held on February 20, 2024, Dr. Robert Huizinga was elected as a director of the Company....

Jan 31, 2024 08:30 am ET

Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel Spray

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that it has filed a patent on its revyve™ Antimicrobial Wound Gel Spray, a follow-on product to its FDA 510(k) cleared revyve™ Antimicrobial Wound Gel,...

Jan 25, 2024 12:03 pm ET

Kane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care Symposium

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium. The international...

Jan 18, 2024 04:30 pm ET

Kane Biotech Announces Special Meeting of Shareholders

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the “Meeting”) to consider the election of Dr. Robert...

Dec 29, 2023 02:33 pm ET

Kane Biotech Announces Correction to Press Release

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) today announces a correction to its press release dated December 28, 2023. The maturity date of the Company’s amended and restated credit facility between Pivot I...

Dec 28, 2023 04:05 pm ET

Kane Biotech Announces Amendment to its Credit Facility

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on December 20, 2023, the Company and Pivot I Financial Limited Partnership (“Pivot”) entered into a definitive agreement to amend the terms of...

Dec 20, 2023 08:29 am ET

Kane Biotech Receives Offer for its Interest in STEM Animal Health

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on December 19, 2023, it signed a non-binding offer for the sale of its interest in STEM Animal Health Inc. (“STEM”). “In 2018, when I...

Nov 28, 2023 04:05 pm ET

Kane Biotech Announces Improved Third Quarter 2023 Financial Results

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2023 financial results. Third Quarter Financial Highlights: Revenue from product and services for the three months ended September 30,...

Nov 21, 2023 07:45 am ET

Kane Biotech to Release Third Quarter 2023 Financial Results on November 28, 2023 – Conference Call to Follow

Nov 16, 2023 01:45 pm ET

Kane Biotech Strengthens Board with Biotech Executive

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) is pleased to announce that John Coleman has been appointed to the Board of Directors of Kane Biotech effective immediately. Dr. Coleman brings a wealth of...

Nov 02, 2023 11:48 am ET

Kane Biotech and ProgenaCare Global Launch Newly Rebranded revyve™ Antimicrobial Wound Gel at Advanced Wound Care Fall Forum

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) in partnership with ProgenaCare Global LLP (“ProgenaCare”) today announces the launch of the newly rebranded revyve™ Antimicrobial Wound Gel (formerly coactiv+™...

Oct 25, 2023 07:45 am ET

Kane Biotech to Exhibit at Symposium on Advanced Wound Care Fall Forum

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it will be unveiling the new brand for its coactiv+™ Antimicrobial Wound Gel product (“Wound Gel”) at the Symposium on Advanced Wound Care Fall forum...

Sep 12, 2023 07:45 am ET

Kane Biotech Announces Closing of Fully Subscribed Private Placement Offering and Amendments to its Credit Facility

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces that on September 11, 2023 it has fully subscribed and closed its previously announced non-brokered private placement offering (the “Offering”) of units...

Aug 29, 2023 04:29 pm ET

Kane Biotech Announces Second Quarter 2023 Financial Results

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its second quarter 2023 financial results. Second Quarter Financial Highlights: Revenue from product and services for the three months ended June...

Aug 22, 2023 07:30 am ET

Kane Biotech to Release Second Quarter 2023 Financial Results on Aug 29, 2023 – Conference Call to Follow

Aug 03, 2023 07:45 am ET

Kane Biotech Announces Private Placement Offering and Proposed Amendments to its Credit Facility

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) today announces its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 6,250,000 units of the Company (“Units”) at a price...

Aug 02, 2023 07:30 am ET

Kane Biotech Engages Research Capital to Conduct Strategic Review of STEM Animal Health

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announced today that it has engaged Research Capital Corporation as Kane’s exclusive financial advisor (the “Advisor”) to conduct a strategic review process for its...

Jun 23, 2023 05:30 pm ET

Kane Biotech Announces Issuance of Restricted Share Units

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has issued 9,703,809 restricted share units of the Company (“RSUs”) to various directors, officers, employees and consultants of the Company...

May 25, 2023 04:05 pm ET

Kane Biotech Announces First Quarter 2023 Financial Results

May 25, 2023 10:48 am ET

IIROC Trading Resumption - KNE

VANCOUVER, BC, May 25, 2023 /CNW/ - Trading resumes in:

May 25, 2023 10:38 am ET

Kane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound Gel

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that on May 24, 2023 it received 510(k) clearance of its coactiv+™ Antimicrobial Wound Gel from the U.S. Food and Drug Administration (FDA) for the management of...

May 25, 2023 08:57 am ET

IIROC Trading Halt - KNE

VANCOUVER, BC, May 25, 2023 /CNW/ - The following issues have been halted by IIROC:

May 18, 2023 04:05 pm ET

Kane Biotech to Release First Quarter 2023 Financial Results on May 25, 2023 – Conference Call to Follow

Apr 20, 2023 04:05 pm ET

Kane Biotech Announces Fourth Quarter and Full Year 2022 Financial Results

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced its fourth quarter and full year 2022 financial results. Fourth Quarter Financial Highlights Total revenue for the three months ended December 31, 2022...

Apr 20, 2023 07:30 am ET

Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its coactiv+™ Antimicrobial Wound Gel

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announced today that it has signed a distribution agreement with ProgenaCare Global LLC (“ProgenaCare”) for its coactiv+™ Antimicrobial Wound Gel in the United...

Apr 18, 2023 07:30 am ET

Kane Biotech Announces Additional coactiv+™ Animal Health Licensing Agreement

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces that it has signed a licensing agreement with Skout’s Honor Pet Supply Company (“Skout’s Honor”) for its patented coactiv+™ technology in pet oral care...

Apr 13, 2023 04:30 pm ET

Kane Biotech to Release Fourth Quarter and Full Year 2022 Financial Results on April 20, 2023 – Conference Call to Follow

Mar 03, 2023 06:41 pm ET

Kane Biotech Clarifies Terms of Credit Facility

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that, as previously announced by the Company in its March 1, 2023 press release, pursuant to the formal amending agreement (the “Amending Agreement”) with Pivot...

Mar 02, 2023 04:32 pm ET

Kane Biotech Announces Amendment to its Credit Facility

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that it has entered into a formal amending agreement (the “Amending Agreement”) with Pivot Financial I Limited Partnership (“Pivot”), to amend the terms of...

Mar 01, 2023 08:53 am ET

Kane Biotech Announces Proposed Amendments to its Credit Facility and Changes to its Board of Directors

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that Pivot Financial I Limited Partnership (“Pivot”) has agreed, in principle, to amend the terms of the Company’s amended and restated credit agreement...

Feb 06, 2023 07:35 am ET

Kane Biotechâs Coactiv+â¢ Technology Could Address a Pricey and Painful Problem: Lack of Healing in Chronic Wounds Due to Microbial Biofilm Formation

By Richard Dal Monte

Feb 06, 2023 07:31 am ET

Kane Biotech Announces Extension of Term of Credit Facility

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) announces today that it has entered into an amending agreement with Pivot Financial I Limited Partnership (“Pivot”) to the amended and restated credit agreement between the Company and...

Jan 04, 2023 07:30 am ET

Kane Biotech Announces First Distribution Agreement for its coactiv+™ Antimicrobial Hydrogel

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has recently signed a distribution agreement with Salud Pharma S.A. (“Salud Pharma”) for its coactiv+™ Antimicrobial Hydrogel wound care and...

Dec 29, 2022 05:34 pm ET

Kane Biotech Announces Loan Transaction

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has reached an agreement to obtain loans (the “Loans”) in the aggregate amount of $2,000,000 from two lenders (the “Lenders”). The Loans will bear...

Nov 24, 2022 04:10 pm ET

Kane Biotech Announces Third Quarter 2022 Financial Results

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2022 financial results. Financial Highlights: Total revenue for the three months ended September 30, 2022 was $571,686 an increase...

Nov 17, 2022 08:30 am ET

Kane Biotech to Release Third Quarter 2022 Financial Results on November 24, 2022 – Conference Call to Follow

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce...

Nov 03, 2022 07:30 am ET

Kane Biotech Announces 510(k) Submission for its coactiv+™ Antimicrobial Hydrogel

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that it has recently submitted a 510(k) premarket notification, which has been received by The Center for Devices and Radiological Health (CDRH) of the U.S. Food...

Oct 13, 2022 04:30 pm ET

Kane Biotech to Present at Symposium on Advanced Wound Care Fall Forum

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that the Company will be presenting at the Symposium on Advanced Wound Care (SAWC) Fall forum. The conference will take place on October 13-16, 2022 in Las...

Oct 04, 2022 08:00 am ET

Kane Biotech Receives an Additional $425K USD of Funding for its DispersinB® Hydrogel from the United States Department of Defense

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has received an additional $425,000 USD of funding for its DispersinB Hydrogel® related to its Medical Technology Enterprise Consortium Research...

Aug 25, 2022 04:12 pm ET

Kane Biotech Announces Second Quarter 2022 Financial Results

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its second quarter 2022 financial results. Second Quarter Financial Highlights: Total revenue for the three months ended June 30, 2022 was $839,579, an...

Aug 18, 2022 04:30 pm ET

Kane Biotech to Release Second Quarter 2022 Financial Results on August 25, 2022 – Conference Call to Follow

Jun 30, 2022 04:05 pm ET

Kane Biotech Announces Adoption of Amended and Restated Stock Option Plan and Performance and Restricted Share Unit Plan

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) announces that, following the approval of the shareholders of the Company (the “Shareholders”) at the annual general and special meeting of Shareholders held on May 26, 2022, the...

Jun 15, 2022 08:00 am ET

Kane Biotech Announces Amended Credit Facility

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has further amended its credit agreement with Pivot Financial Inc. (“Pivot”) maturing August 31, 2022 (the “Amended Credit Facility”). The...

May 26, 2022 04:05 pm ET

Kane Biotech Announces First Quarter 2022 Financial Results

May 19, 2022 08:30 am ET

Kane Biotech to Release First Quarter 2022 Financial Results on May 26 – Conference Call to Follow

May 18, 2022 08:30 am ET

Kane Biotech Obtains ISO 13485 Certification

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announced today that it has obtained ISO 13485:2016 certification for its quality management system specific to its ongoing efforts to design and develop novel medical...

May 17, 2022 07:00 am ET

Kane Biotech Announces Closing of Private Placement

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) is pleased to announce that it has closed its non-brokered private placement offering (the “Offering”) announced previously on March 15, 2022, and has issued 10,000,000 common shares...

May 06, 2022 08:30 am ET

Kane Biotech Announces Update on Private Placement

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech,” or the “Company”), announced that its private placement of up to 10,000,000 common shares (“Shares”) at a price of $0.10 per Share for aggregate gross proceeds of up to $1,000,000, as...

Apr 29, 2022 04:05 pm ET

Kane Biotech Announces Extension of Private Placement Offering

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today announced that it has extended the completion of its previously announced non-brokered private placement offering (the “Offering”) by 30 days until May 29, 2022. The terms of...

Apr 07, 2022 12:56 pm ET

IIROC Trading Resumption - KNE

VANCOUVER, BC, April 7, 2022 /CNW/ - Trading resumes in:

Apr 07, 2022 12:40 pm ET

STEM Animal Health Awarded Veterinary Oral Health Council (VOHC) Seal of Acceptance for Pet Oral Care Water Additive

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), is pleased to announce today that STEM Animal Health Inc. (“STEM”) has been awarded the prestigious Veterinary Oral Health Council (VOHC) Seal of Acceptance in the Helps...

Apr 07, 2022 10:47 am ET

IIROC Trading Halt - KNE

VANCOUVER, BC, April 7, 2022 /CNW/ - The following issues have been halted by IIROC:

Apr 05, 2022 08:00 am ET

Kane Biotech Appoints Dr. Gregory Schultz as Chief Scientific Officer

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announced today the appointment of Gregory Schultz, PhD, a world renowned expert on biofilms, as Chief Scientific Officer (CSO). “As a world-renowned expert in wound...

Mar 24, 2022 04:05 pm ET

Kane Biotech Announces Fourth Quarter and Full Year 2021 Financial Results

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced its fourth quarter and full year 2021 financial results. Fourth Quarter Financial Highlights Total Revenue for the three months ended December 31, 2021...

Mar 22, 2022 08:00 am ET

Kane Biotech Successfully Completes Safety and Biocompatibility Studies for DispersinB® Wound Gel in Preparation for Human Clinical Trials

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech,” or “the Company”) announced positive results from biocompatibility and in vivo safety studies in preparation for human clinical trials set to begin later this year. DispersinB® wound gel...

Mar 17, 2022 07:00 am ET

Kane Biotech to Release Fourth Quarter and Full Year 2021 Financial Results on March 24 – Conference Call to Follow

Mar 15, 2022 07:00 am ET

Kane Biotech Announces Private Placement Offering

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today announced its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 10,000,000 common shares (“Shares”) at a price of $0.10 per Share for...

Feb 10, 2022 08:00 am ET

Kane Biotech Announces New Collaboration Agreements for Prosthetic Joint Infection, expanding its DispersinB® applications

Kane Biotech Inc. announces that it has signed collaboration agreements with Dr. James Doub, MD, Assistant Professor of Medicine, University of Maryland School of Medicine’s Institute of Human Virology, and the University of Texas Medical Branch...

Jan 20, 2022 12:00 pm ET

Wound Care Commercialization to be a Key Company Focus in 2022

Kane Biotech CEO, Marc Edwards sees its rich 20-year history of biofilm research and product development as a real strategic advantage in the wound care and surgical markets. “Biofilms in wound care have been an increasing topic of discussion...

Nov 16, 2021 04:00 pm ET

Kane Biotech Announces Third Quarter 2021 Financial Results

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced their third quarter 2021 financial results. Third Quarter Financial Highlights Revenue from product sales in the three months ended September 30, 2021...

Nov 09, 2021 08:00 am ET

Kane Biotech to Release Third Quarter 2021 Financial Results on November 16 – Conference Call to Follow

Sep 02, 2021 08:00 am ET

Kane Biotech Announces New Credit Facility

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has entered into an amended and restated credit agreement with Pivot Financial Inc. (“Pivot”) dated August 31, 2021 (the “Amended Credit...

Aug 31, 2021 08:00 am ET

STEM Animal Health completes first shipment of bluestem™ oral care products to PetSmart® Canada

Kane Biotech Inc. announces that STEM Animal Health Inc., has shipped its first order of bluestem™ products to PetSmart® Canada, Canada largest specialty pet retailer of services and solutions for the lifetime needs of pets. Bluestem™ oral care...

Aug 26, 2021 04:00 pm ET

Kane Biotech Announces Second Quarter 2021 Financial Results

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its Second Quarter 2021 financial results. Second Quarter Financial Highlights Total revenue in the three months ended June 30, 2021 was $278,741...

Aug 19, 2021 04:00 pm ET

Kane Biotech to Release Second Quarter 2021 Financial Results on August 26 – Conference Call to Follow

Jul 29, 2021 08:00 am ET

Kane Biotech Receives Decisions to Grant for Two European Patents Providing Broad Protection of coactiv+™ Technology for Wound Care, Skin Infections and Personal Care Formulations

Kane Biotech Inc. announces that it has received two Decisions to Grant from the European Patent Office for patents covering its best-in-class coactiv+™ technology. The allowed claims cover composition of matter for the company's proprietary...

Jul 22, 2021 08:00 am ET

Kane Biotech Expands its Wound Care and Surgical Portfolio with a coactiv+TM Antimicrobial Hydrogel

Kane Biotech Inc. announces plans to expand its wound care and surgical portfolio with an antimicrobial hydrogel based on its best-in-class coactiv+™ technology. Kane has already demonstrated efficacy of its patented coactiv+TM technology in both...

Jul 21, 2021 04:30 pm ET

Kane Biotech Announces Cancellation of Options and Issuance of Restricted Share Units

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has cancelled 8,470,555 stock options of the Company (the “Cancelled Options”) of various directors, officers, employees and consultants of the...

Jul 13, 2021 08:00 am ET

Kane Biotech announces two key milestones as DispersinB® wound care project advances towards human clinical trials

Kane Biotech Inc. announces that it has successfully prepared its first batch of DispersinB® wound care hydrogel, intended for use in pre-clinical studies which will begin this quarter. This novel formulation, based on a recently filed patent...

Jun 29, 2021 10:00 am ET

Kane Biotech to meet investors at Whistler 2021 Capital Conference

Kane Biotech Inc. will host investor meetings at the 10th Annual Whistler 2021 Capital Conference hosted by Capital Event Management the weekend of July 9-11, 2021 at The Fairmont Chateau, Whistler. Kane Chief Executive Officer, Marc Edwards will...

Jun 16, 2021 10:00 am ET

Kane Biotech launches 2021 business update series

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), goes live today with the first of a 5-part “2021 business update” video series. Meant to offer investors and other stakeholders bite-sized explainers that discuss and...

Jun 09, 2021 04:00 pm ET

Kane Biotech Announces Adoption of Performance and Restricted Share Unit Plan and Amended and Restated Stock Option Plan

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announced that, at the annual and special meeting of shareholders of Company (“Shareholders”) held on May 26, 2021 (the “Meeting”), by ordinary resolution, a...

May 27, 2021 04:00 pm ET

Kane Biotech Announces First Quarter 2021 Financial Results

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced first quarter 2021 financial results. First Quarter Financial Highlights Revenue from product sales in the three months ended March 31, 2021 was...

May 20, 2021 08:00 am ET

Kane Biotech to Release First Quarter 2021 Financial Results on May 27 – Conference Call to Follow

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce...

Apr 29, 2021 08:00 am ET

Kane Biotech Announces Strong Positive Results of DermaKB™ Shampoo Consumer Trial

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), is pleased to announce that it has published strong positive results from a recent consumer trial of its DermaKB™ products. Kane Biotech recently published on its...

Apr 13, 2021 08:00 am ET

Kane Biotech Strengthens Board with Biotech Executive

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), is pleased to announce that Dr. Allan Mandelzys has been engaged as an advisor to Kane Biotech’s Board of Directors and will be nominated for Board directorship at the...

Mar 25, 2021 04:00 pm ET

Kane Biotech Announces Fourth Quarter and Full Year 2020 Financial Results

Mar 18, 2021 04:30 pm ET

Kane Biotech to Release Fourth Quarter and Full Year 2020 Financial Results on March 25 – Conference Call to Follow

Mar 11, 2021 08:00 am ET

Kane Biotech to Participate in Maxim Group LLC Inaugural Emerging Growth Conference

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane”), announced today that Marc Edwards, CEO will be presenting at the Inaugural Emerging Growth Virtual Conference presented by Maxim Group LLC. The conference will take place on...

Mar 10, 2021 08:00 am ET

Kane Biotech Announces Positive Efficacy Results in STEM Pet Oral Care Clinical Trial

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane”), announced today that preliminary analysis of data from efficacy trials for STEM Animal Health Inc.’s (“STEM”) pet oral care water additive have met the primary endpoint. As...

Feb 24, 2021 08:45 am ET

Kane Biotech Announces New Chairman

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announced today current Board member Mark Nawacki will take over as Chairman of the Board, and Philip Renaud will assume the role of Vice Chair. “Over the past two...

Dec 21, 2020 08:35 am ET

Life Sciences Company Investor Presentations Now Available for On-Demand Viewing

Life Sciences Investor Forum today announced that the presentations from the December 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive...

Dec 14, 2020 08:28 am ET

Virtual Conference for Life Sciences Companies Broadcast Live December 17th, 2020

Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...

Dec 10, 2020 01:34 pm ET

CORRECTION -- Kane Biotech to Webcast Live at Life Sciences Investor Forum on December 17

In a release issued under the same headline yesterday December 9, 2020 by OTC Markets please note that the presentation time has been changed from 9:30 PM ET to 9:30 AM ET, and an edit was made in the first paragraph. The corrected release follows:...

Dec 10, 2020 08:30 am ET

Kane Biotech Announces Launch of New Human Health OTC DermaKB™ Product Line

Dec 09, 2020 08:35 am ET

Kane Biotech to Webcast Live at Life Sciences Investor Forum on December 17

Kane Biotech Inc. (TSX-V: KNE; OTCQB:KNBIF), a biotechnology company engaged in research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Today announced that Marc Edwards, CEO, will...

Nov 26, 2020 05:30 pm ET

Kane Biotech Announces Third Quarter 2020 Financial Results

Nov 19, 2020 05:30 pm ET

Kane Biotech to Release Third Quarter 2020 Financial Results on November 26 – Conference Call to Follow

Nov 05, 2020 05:00 pm ET

Kane Biotech Enters into Credit Facility with Pivot Financial

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”) today announced that it has entered into a one year credit agreement (the “Credit Agreement”) with Pivot Financial Inc. (“Pivot”) for a non-revolving term loan in the aggregate amount of...

Oct 28, 2020 08:00 am ET

Kane Biotech builds upon successful results with launch of a US Consumer Test

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech,” or “the Company”) is pleased to announce that the launch of a larger consumer product test to further prove the efficacy of the Company’s shampoo on dermatitis and dandruff began on...

Oct 13, 2020 08:00 am ET

STEM Animal Health Appoints New President and CEO

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”) today announced that Kevin Cole will assume the role of President and CEO of STEM Animal Health Inc. (“STEM”), a subsidiary created from the recently formed joint venture with UK-based...

Sep 28, 2020 10:02 am ET

IIROC Trading Resumption - KNE

VANCOUVER, BC, Sept. 28, 2020 /CNW/ - Trading resumes in:

Sep 28, 2020 09:45 am ET

Kane Biotech and Animalcare to Form Animal Health Company to Target Biofilm-Related Ailments

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”) today announced that it has entered into an agreement with UK-based veterinary products company, Animalcare Group PLC (AIM:ANCR,”Animalcare”), under which the parties will form STEM...

Sep 28, 2020 08:13 am ET

IIROC Trading Halt - KNE

VANCOUVER, BC, Sept. 28, 2020 /CNW/ - The following issues have been halted by IIROC:

Sep 23, 2020 08:00 am ET

Kane Biotech Appoints New Advisor

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Company,” “Kane Biotech”) today announced that it has entered into an agreement with Harbor Access LLC (“Harbor Access”), an investor relations advisory firm with offices in Canada and the United States....

Sep 09, 2020 04:30 pm ET

Kane Biotech to be Featured in Medtech Webinar Hosted by Alliance Global Partners

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today...

Aug 27, 2020 04:02 pm ET

Kane Biotech Announces Second Quarter 2020 Financial Results

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today...

Aug 20, 2020 04:30 pm ET

Kane Biotech to Release Second Quarter 2020 Financial Results on August 27 – Conference Call to Follow

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce...

Aug 20, 2020 08:00 am ET

Kane Biotech Announces Grant of Stock Options

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today announces that on August 19, 2020 it granted an aggregate of 2,310,555 stock options (the "Options") to certain directors, officers, employees and consultants of the Company in...

Aug 12, 2020 08:00 am ET

Kane Biotech Appoints Wound Care and Biofilms Expert, Dr. Gregory Schultz, as Scientific Advisor

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that Gregory Schultz, Ph.D., has been appointed as a Scientific Advisor. Dr. Schultz is the Director of the Institute for Wound Research and Professor...

Jun 24, 2020 08:15 am ET

Kane Biotech Receives New Funding from CanExport SMEs Program

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that it has been approved for up to $54,750 in funding from the Government of Canada’s CanExport SMEs program. Kane will use this funding to support the...

Jun 18, 2020 02:34 pm ET

IIROC TSXV Business Resumption - KNE

VANCOUVER, BC, June 18, 2020 /CNW/ - Trading resumes in:

Jun 18, 2020 02:26 pm ET

Kane Biotech Receives $2.7 Million USD United States Department of Defense Award for DispersinB®

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that, further to its press releases of January 17, 2019 and December 4, 2019, its proposal entitled “DispersinB® the missing link in wound care – Clinical...

Jun 18, 2020 11:55 am ET

IIROC Trading Halt - KNE

VANCOUVER, BC, June 18, 2020 /CNW/ - The following issues have been halted by IIROC:

May 21, 2020 04:02 pm ET

Kane Biotech Announces First Quarter 2020 Financial Results

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced its first...

May 19, 2020 08:00 am ET

Kane Biotech Recommences Trading on the OTCQB Venture Market

May 14, 2020 04:30 pm ET

Kane Biotech to Release First Quarter 2020 Financial Results on May 21 – Conference Call to Follow

May 14, 2020 08:00 am ET

Kane Biotech Announces Further Extension of Warrants

Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane Biotech”), today announced that it has further amended the terms of its 34,504,997 common share purchase warrants (the “Warrants”) issued on July 17, 2017 (the “Initial Closing”) and August...

May 12, 2020 04:02 pm ET

Kane Biotech Reports Positive Results from Anti-Biofilm Shampoo Consumer Product Test

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today announced positive results from a consumer product test evaluating the efficacy of its shampoo on dermatitis and dandruff. Kane Biotech’s shampoo was developed based on research...

May 12, 2020 08:00 am ET

Kane Biotech Reports Positive Results from Anti-Biofilm Shampoo Consumer Product Test

May 07, 2020 08:00 am ET

Kane Biotech Provides an Update Regarding Its Response to COVID-19

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today provided an update on the actions the Company has taken in response to the global COVID-19 pandemic. Kane Biotech continues to monitor and implement recommendations from local...

Apr 02, 2020 04:02 pm ET

Kane Biotech Announces Fourth Quarter and Full Year 2019 Financial Results

Mar 25, 2020 04:57 pm ET

Kane Biotech Reschedules Release of Fourth Quarter and Full Year 2019 Financial Results and Associated Conference Call to April 2, 2020

Further to its press release of March 20, 2020, Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company) announced that, in response to the evolving dynamics related to the COVID-19 pandemic, it has decided to delay the release of its fourth...

Mar 20, 2020 08:00 am ET

Kane Biotech to Release Fourth Quarter and Full Year 2019 Financial Results on March 26 – Conference Call to Follow

Mar 02, 2020 04:30 pm ET

Kane Biotech Announces Grant of Stock Options

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today announces that it granted an aggregate of 3,650,000 stock options (the "Options") to certain directors, officers, employees and consultants of the Company in accordance with the...

Feb 26, 2020 08:00 am ET

Kane Biotech Launches silkstem™ Anti-Itch Shampoo at the Global Pet Expo

Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced the...

Feb 25, 2020 08:00 am ET

Kane Biotech Signs First U.S. Distribution Agreement with King Wholesale Inc.

Feb 24, 2020 04:35 pm ET

Kane Biotech Announces Closing of Second and Final Tranche of Private Placement

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) is pleased to announce that it has closed the second tranche (the “Second Tranche”) of its non-brokered private placement offering (the “Offering”) previously announced on December 4,...

Feb 20, 2020 08:00 am ET

Kane Biotech Welcomes Renowned Canadian Veterinarian, Dr. Jean Gauvin, as Chief Veterinary Officer

Jan 27, 2020 08:00 am ET

Kane Biotech Engages Independent Trading Group, Inc. for Market-Making Services

Jan 23, 2020 05:00 pm ET

Kane Biotech Provides Update on Previously Announced Private Placement

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”), in accordance with the policies of the TSX Venture Exchange (“TSX-V”), wishes to provide an update on the status of the non-brokered private placement of the Company’s units (“Units”...

Dec 19, 2019 05:00 pm ET

Kane Biotech Announces Closing of First Tranche of Private Placement

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) is pleased to announce that it has closed the first tranche (the “First Tranche”) of its non-brokered private placement offering (the “Offering”) announced previously on December 4,...

Dec 17, 2019 04:15 pm ET

Kane Biotech Announces Fulfilment of First Major Animal Oral Care Product Order from China

Dec 16, 2019 04:15 pm ET

Kane Biotech Launches Consumer Product Test for an Innovative Shampoo Containing its Patented Anti-Biofilm Technology

Dec 04, 2019 08:00 am ET

Kane Biotech Announces Private Placement Offering

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today announced its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 25,000,000 units (“Units”) at a price of $0.14 per Unit for gross...

Dec 03, 2019 08:00 am ET

Kane Biotech Announces Conditional Research Award of Up To $3.4 Million

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today announced that it has been selected to receive a potential award of up to approximately $3.4 million from an unnamed government agency related to the continuing clinical...

Dec 02, 2019 04:30 pm ET

Kane Biotech to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) announced today that management will present an update on the Company’s business at the first annual BioTuesdays Pre-JPM Virtual Conference on Tuesday, December 10, 2019 at 2:00 p.m....

Nov 26, 2019 08:00 am ET

Kane Biotech Engages Kilmer Lucas for Cross-Border Investor Relations

Nov 14, 2019 04:15 pm ET

Kane Biotech Announces Third Quarter 2019 Financial Results

Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announces its...

Nov 06, 2019 04:30 pm ET

Kane Biotech Announces Date of Q3 Earnings Release

Oct 31, 2019 06:55 am ET

Kane Biotech Retains GR Consulting to Identify Potential Partnerships for its Proprietary DispersinB® Wound Care Hydrogel

Kane Biotech Inc. (TSX-V: KNE), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, is pleased to...

Oct 16, 2019 06:55 am ET

Kane Biotech and Dechra Veterinary Products Expand Exclusive License and Distribution Agreement to Include South America

Oct 08, 2019 06:55 am ET

Kane Biotech Receives Funding for Research and Development

Kane Biotech Inc. (TSX-V: KNE), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, is pleased to...

Sep 10, 2019 04:30 pm ET

Kane Biotech Releases Inaugural Business Update Video

Kane Biotech Inc. (TSX-V: KNE), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today hosted their...

Aug 21, 2019 04:30 pm ET

Kane Biotech Announces Second Quarter 2019 Financial Results

Aug 14, 2019 06:55 am ET

Kane Biotech Announces Q2 Earnings Release and Inaugural Business Update Video

Aug 13, 2019 06:55 am ET

Kane Biotech Announces Share Purchase by CEO, Exercise of Warrants, Reimbursement of Insider Advances and Extension of Loan

Aug 12, 2019 06:55 am ET

Kane Biotech Strengthens Team with New Additions in Animal Health and Quality Assurance

Aug 06, 2019 11:11 am ET

IIROC Trading Resumption - KNE

VANCOUVER, Aug. 6, 2019 /CNW/ - Trading resumes in:

Aug 06, 2019 11:05 am ET

Kane Biotech Awarded $3.8 Million in Non-Dilutive Government Funding

Aug 06, 2019 08:09 am ET

IIROC Trading Halt - KNE

VANCOUVER, Aug. 6, 2019 /CNW/ - The following issues have been halted by IIROC:

Aug 01, 2019 04:30 pm ET

Kane Biotech Announces New Funding Granted from CanExport Program

Jul 18, 2019 06:55 am ET

Kane Biotech Announces Exclusive Distribution Agreement with Eetoys Pet Products Limited

Jul 16, 2019 06:55 am ET

Kane Biotech Announces New Agreement with FreeMind Group

Jun 25, 2019 06:55 am ET

Kane Biotech Secures Large Order from Leading Quebec Retailer

Jun 20, 2019 10:33 am ET

IIROC Trading Resumption - KNE

VANCOUVER, June 20, 2019 /CNW/ - Trading resumes in:

Jun 20, 2019 10:23 am ET

Kane Biotech and Nestlé Reach Settlement

Jun 20, 2019 08:14 am ET

IIROC Trading Halt - KNE

VANCOUVER, June 20, 2019 /CNW/ - The following issues have been halted by IIROC:

May 29, 2019 04:15 pm ET

Kane Biotech to Showcase Technologies and Products at the 2019 BIO International Convention

May 22, 2019 04:15 pm ET

Kane Biotech Announces First Quarter 2019 Financial Results, Extension of Loan and Insider Funding

May 16, 2019 04:15 pm ET

Kane Biotech Announces First Quarter 2019 Earnings Conference Call and Business Update

Apr 30, 2019 06:55 am ET

Kane Biotech Provides Update on Exclusive License and Distribution Agreement with Dechra Veterinary Products

Apr 24, 2019 06:55 am ET

Kane Biotech Announces New Sales Representation by SLA Brands

Apr 17, 2019 04:15 pm ET

Kane Biotech Announces Granting of Options

Mar 25, 2019 04:15 pm ET

Kane Biotech Announces Fourth Quarter and Full Year 2018 Financial Results

Mar 20, 2019 04:30 pm ET

Kane Biotech Schedules Full Year 2018 Earnings Conference Call and Business Update

Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane Biotech”), is pleased to announce today that it will host a conference call and webcast on Tuesday, March 26, 2019 at 4:00pm Eastern Time to discuss its financial results for the fourth...

Feb 19, 2019 06:50 am ET

Kane Biotech Signs Distribution Agreement and Secures First Order from China

Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane Biotech”), is pleased to announce that it has signed a non-exclusive Distribution Agreement with a major Chinese distributor and secured its first order valued at $25K USD. The order...

Feb 04, 2019 08:30 am ET

Eastern Missouri Court Rules in Favor of Kane Biotech in Lawsuit Against Nestle Purina

Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane Biotech”), is pleased to announce that the U.S. District Court of Eastern Missouri that is overseeing the lawsuit filed by Kane Biotech against Nestec, Ltd., aka Nestec, S.A., Nestle Purina...

Jan 30, 2019 08:30 am ET

Kane Biotech Expands Previously-Announced Single Largest Order of bluestem™ Products

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), is pleased to announce that it has secured an additional purchase order for bluestem™ products, from the North American pet retail chain that recently purchased the...

Jan 25, 2019 08:30 am ET

Kane Biotech to Host Investor Town Hall Webcast and Conference Call

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), is pleased to announce today that it will host a conference call and webcast on Wednesday, January 30, 2019 at 4:00pm Eastern Time to provide an update on the...

Jan 24, 2019 08:30 am ET

Kane Biotech Secures Largest Single Order of bluestem™ products

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), is pleased to announced that it has closed and delivered its single largest purchase order in the history of the company for C$440K of bluestem products to one of...

Jan 17, 2019 09:00 am ET

Kane Biotech Positions DispersinB® for Wound Care treatment in United States: Applies for U.S. Army Medical Research Funding and renews commitment to Rutgers University

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), announced today the kick-off of their new human health strategy. Efforts will be focused on development of a wound care hydrogel containing Kane’s patented enzyme...

Dec 12, 2018 08:30 am ET

Kane Biotech Launches Four New bluestem™ Products

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), today announced it will be launching 4 new products under its bluestem™ brand in Canada and the United States in the first quarter of 2019. The four products to...

Nov 14, 2018 06:09 pm ET

Kane Biotech Announces Third Quarter 2018 Financial Results

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF) (the “Corporation” or “Kane Biotech”) announces its Third Quarter 2018 Financial Results. Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of...

Nov 12, 2018 04:30 pm ET

Kane Biotech Announces Extension of Warrants

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), today announced that it has amended the terms of its 34,504,997 common share purchase warrants (the “Warrants”) issued on July 17, 2017 (the “Initial Closing”) and...

Nov 09, 2018 08:30 am ET

Kane Biotech Records Significant Online Sales Growth from Amazon

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), today announced that it has experienced significant year-over-year growth in online sales of its bluestem™ brand of oral care products on Amazon. Combined sales on...

Nov 08, 2018 08:28 am ET

Kane Biotech Schedules Third Quarter 2018 Earnings Conference Call and Business Update

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce that it will host a conference call on Thursday, November 15, 2018 at 4:30pm E.T. to discuss its financial results for the third quarter 2018,...

Nov 07, 2018 08:30 am ET

Kane Biotech Senior Management Purchases 1.9 Million Shares

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), today announced that Marc Edwards, Chief Executive Officer, and Ray Dupuis, Chief Financial Officer of Kane Biotech recently completed the purchases, from the open...

Nov 05, 2018 04:30 pm ET

Kane Biotech Appoints Dr. Gordon Guay as Chief Scientific Officer

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), today announced the appointment of Gordon Guay, Ph.D., a member of Kane’s Scientific Advisory Board (SAB), to Chief Scientific Officer of the Company. Dr. Guay’s...

Oct 17, 2018 05:30 pm ET

Kane Biotech Announces New Manufacturing Partner for bluestem™ Product Line

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), today announced it has signed an agreement with Nature Soap Spa, a Winnipeg-based company whose Director has more than 30 years of experience in GMP-certified...

Sep 24, 2018 04:30 pm ET

Kane Biotech Announces Formation of Scientific Advisory Board

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), today announced the formation of a Scientific Advisory Board (SAB), chaired by Kane Biotech Board Director Rivka Gluck, and will work closely with senior management...

Sep 11, 2018 04:31 pm ET

Kane Biotech Announces Departure of CEO

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) today announced that Mark Ahrens-Townsend has departed from the Company as Chief Executive Officer as of September 10, 2018. Mark will remain close to the Company and...

Aug 21, 2018 05:33 pm ET

Kane Biotech Announces Second Quarter 2018 Financial Results

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF) (the “Corporation” or “Kane Biotech”) announces its Second Quarter 2018 Financial Results. Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of...

Aug 15, 2018 04:34 pm ET

Kane Biotech Schedules Second Quarter 2018 Earnings Conference Call and Business Update

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce that it will host a conference call on Wednesday, August 22, 2018 at 4:30pm E.T. to discuss its financial results for the second quarter 2018,...

Aug 14, 2018 08:00 am ET

Kane Biotech Achieves DTC Eligibility in the United States

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce that the Corporation has secured eligibility by The Depository Trust Company ("DTC") for its shares on the OTCQB Venture Market. DTC is a New...

Aug 09, 2018 05:06 pm ET

Kane Biotech Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) today announced the engagement of Dave D. Hood, President and Chief Executive Officer of DH3 Associates, as a strategic consultant to help secure non-dilutive...

Jul 31, 2018 08:00 am ET

Kane Biotech and the U.S. Army Institute of Surgical Research Sign Extension of Cooperative Research and Development Agreement

Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce a three year Cooperative Research and Development Agreement (CRADA) extension has been signed with the U.S. Army Institute of Surgical Research...

Jul 24, 2018 04:13 pm ET

Kane Biotech Retains Market-Making Services

Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) today announced it has, subject to regulatory approval, agreed to retain Venture Liquidity Providers Inc. (“VLP”) to initiate its market-making service to provide...

Jul 17, 2018 06:30 pm ET

Kane Biotech Announces Closing of Loan Transaction

Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) today announced that it has received a loan (the “Loan”) in the amount of $500,000 from Individual Investment Corporation, an arm’s length third-party lender (the...

Jun 21, 2018 05:41 pm ET

Kane Biotech to Showcase bluestem™ Pet Oral Care Products and New Skin Care Shampoo at SuperZoo

Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce that it will be attending SuperZoo, North America’s leading pet retail trade exposition and conference, taking place June 26-28, 2018 at the...

Jun 14, 2018 08:39 am ET

Kane Biotech to Present at The MicroCap Conference in Toronto

Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce that it will present at The MicroCap Conference being held in Toronto on June 21, 2018. Mark Ahrens-Townsend, President CEO of Kane Biotech,...

Jun 01, 2018 08:00 am ET

Kane Biotech to Showcase Technologies and Products at the 2018 BIO International Convention

Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce that it will be attending the 2018 BIO International Convention being held June 4-7, 2018 at the Boston Convention Center in Boston, MA. Mark...

May 31, 2018 01:43 pm ET

IIROC Trading Resumption - KNE

VANCOUVER, May 31, 2018 /CNW/ - Trading resumes in:

May 31, 2018 01:26 pm ET

Kane Biotech Granted Wound Care Patent from the U.S. Patent and Trademark Office

Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF) (the “Corporation” or “Kane Biotech”) is pleased to announce it has been granted a significant patent in the area of wound care by the U.S. Patent and Trademark Office (the “USPTO”). The patent is titled...

May 31, 2018 11:10 am ET

IIROC Trading Halt - KNE

VANCOUVER, May 31, 2018 /CNW/ - The following issues have been halted by IIROC:

May 30, 2018 11:23 am ET

InvestmentPitch Media Invites Investors to the TakeStock Alberta Investor Forum in Calgary on May 31, 2018 - Video Hosted on InvestmentPitch.com

Vancouver, British Columbia--(Newsfile Corp. - May 30, 2018) - As a proud media sponsor, InvestmentPitch Media would like to invite investors to the latest TakeStock Alberta Investor Forum in Calgary on May 31st, 2018 at the Calgary Petroleum Club at 319 5th Avenue SW, from 8:30 am to 5:30 pm.

May 24, 2018 04:30 pm ET

Ad blocking detected

Kane Biotech Inc. (V:KNE)

Business Focus: Biotechnology & Medical Research (NEC)